No abstract

August 16, 1991) ABSTRACT Recombinant soluble CD4 (rsCD4) has potent antiviral activity against cell line-adapted isolates of the human immunodeficiency virus type 1 (iHV-1) but low activity toward H1V-1 primary isolates from patients. A simple hypothesis proposed to explain this discrepancy, which questions the therapeutic utility of soluble CD4-based approaches, is that the major envelope glycoprotein, gpl20, of patient virus has lower

No abstract

No abstract